Opinion|Videos|June 24, 2024

Selecting Optimal Treatment in BCG-Unresponsive NMIBC

Author(s)Gordon A. Brown, DO, Siamak Daneshmand, MD, Jason M. Hafron, MD, CMO

A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Episodes in this series

A panel of 5 experts on bladder cancer

EP. 1 Navigating BCG Shortages in NMIBC

A panel of 5 experts on bladder cancer

EP. 2 The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

A panel of 5 experts on bladder cancer

EP. 3 Efficacy and Safety Data from SunRISe-1

A panel of 5 experts on bladder cancer

EP. 4 Overview of the QUILT Trial in BCG-Unresponsive NMIBC

A panel of 5 experts on bladder cancer

EP. 5 Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

A panel of 5 experts on bladder cancer

EP. 6 Adverse Effect Management and the Role of Immunotherapy in NMIBC

A panel of 5 experts on bladder cancer

EP. 7 Selecting Optimal Treatment in BCG-Unresponsive NMIBC

A panel of 5 experts on bladder cancer

EP. 8 Patient Monitoring Strategies in BCG-Unresponsive NMIBC

A panel of 5 experts on bladder cancer

EP. 9 Promising Developments in NMIBC

A panel of 5 experts on bladder cancer

EP. 10 Key Takeaways on the Evolving NMIBC Treatment Landscape

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Alternative BCG strains may help address ongoing supply challenges in NMIBC

ByEugene B. Cone, MD

September 11th 2026

Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC

ByHannah Clarke

September 10th 2026

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

ByJohn P. Sfakianos, MD

September 9th 2026

Dabogratinib shows early activity in FGFR3-altered LG-IR-NMIBC

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Doublet or triplet? Urologists weighs in on mCSPC options

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

Alternative BCG strains may help address ongoing supply challenges in NMIBC